Literature DB >> 16042235

Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis.

E T Lim1, T Berger, M Reindl, C M Dalton, K Fernando, G Keir, E J Thompson, D H Miller, G Giovannoni.   

Abstract

This study investigates whether the presence of serum and plasma anti-myelin oligodendrocyte glycoprotein (MOG) and anti-myelin basic protein (MBP) in patients presenting with a clinically isolated syndrome compatible with demyelination (CIS) predicts early conversion to multiple sclerosis (MS). Forty-seven patients with CIS (46 with optic neuritis) had anti-MOG and anti-MBP antibodies analysed at baseline, and clinical and magnetic resonance imaging assessments. There was no evidence that the MS status based on either the McDonald or Poser criteria relates to the antibody status.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16042235     DOI: 10.1191/1352458505ms1187sr

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  18 in total

1.  Anti-myelin antibodies in multiple sclerosis: clinically useful?

Authors:  C H Polman; J Killestein
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06       Impact factor: 10.154

2.  Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

Authors:  H Wiendl; K V Toyka; P Rieckmann; R Gold; H-P Hartung; R Hohlfeld
Journal:  J Neurol       Date:  2008-10-29       Impact factor: 4.849

3.  Elevated intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis.

Authors:  Eric C Klawiter; Laura Piccio; Jeri-Anne Lyons; Robert Mikesell; Kevin C O'Connor; Anne H Cross
Journal:  Arch Neurol       Date:  2010-09

4.  Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event.

Authors:  S Rauer; B Euler; M Reindl; Th Berger
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06       Impact factor: 10.154

5.  Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF.

Authors:  Jens Kuhle; Raija L P Lindberg; Axel Regeniter; Matthias Mehling; Francine Hoffmann; Markus Reindl; Thomas Berger; Ernst W Radue; David Leppert; Ludwig Kappos
Journal:  J Neurol       Date:  2007-02       Impact factor: 4.849

Review 6.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

7.  Autoantibodies to Non-myelin Antigens as Contributors to the Pathogenesis of Multiple Sclerosis.

Authors:  Michael C Levin; Sangmin Lee; Lidia A Gardner; Yoojin Shin; Joshua N Douglas; Chelsea Cooper
Journal:  J Clin Cell Immunol       Date:  2013-06-30

Review 8.  [Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis].

Authors:  C Kleinschnitz; S G Meuth; B C Kieseier; H Wiendl
Journal:  Nervenarzt       Date:  2007-08       Impact factor: 1.214

9.  Sera of glaucoma patients show autoantibodies against myelin basic protein and complex autoantibody profiles against human optic nerve antigens.

Authors:  Stephanie C Joachim; Jan Reichelt; Simone Berneiser; Norbert Pfeiffer; Franz H Grus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-01-12       Impact factor: 3.117

Review 10.  B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases.

Authors:  Katherine A McLaughlin; Kai W Wucherpfennig
Journal:  Adv Immunol       Date:  2008       Impact factor: 3.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.